Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
VBLT POWR Grades
- VBLT scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.37% of US stocks.
- The strongest trend for VBLT is in Momentum, which has been heading down over the past 31 weeks.
- VBLT ranks lowest in Momentum; there it ranks in the 9th percentile.
VBLT Stock Summary
- Vascular Biogenics Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 9.2% of US listed stocks.
- Of note is the ratio of Vascular Biogenics Ltd's sales and general administrative expense to its total operating expenses; only 11.05% of US stocks have a lower such ratio.
- VBLT's price/sales ratio is 173.64; that's higher than the P/S ratio of 97.33% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Vascular Biogenics Ltd are AYLA, AUTL, CLDX, PLRX, and COCP.
- Visit VBLT's SEC page to see the company's official filings. To visit the company's web site, go to www.vblrx.com.
VBLT Price Target
For more insight on analysts targets of VBLT, see our VBLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.75 | Average Broker Recommendation | 1.33 (Strong Buy) |
VBLT Stock Price Chart Interactive Chart >
VBLT Price/Volume Stats
| Current price | $2.33 | 52-week high | $3.17 |
| Prev. close | $2.33 | 52-week low | $1.01 |
| Day low | $2.30 | Volume | 118,851 |
| Day high | $2.36 | Avg. volume | 901,948 |
| 50-day MA | $2.15 | Dividend yield | N/A |
| 200-day MA | $1.83 | Market Cap | 112.28M |
Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio
Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.
Latest VBLT News From Around the Web
Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.
Vascular Biogenics, Ltd. Investors: Company Investigated by the Portnoy Law FirmInvestors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vascular Biogenics, Ltd. ("VBL" or the "Company") (NASDAQ: VBLT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLTPomerantz LLP is investigating claims on behalf of investors of Vascular Biogenics Ltd. ("VBL" or the "Company") (NASDAQ: VBLT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. |
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian CancerTEL AVIV, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The Company was notified by the U.S Food and Drug Administration (FDA) that clearance of new VB-111 batches for use in the U.S. is currently pending the completion of a technical review by the Chemistry, Manufacturing, and Controls (CMC) group, which is |
VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendmentwildpixel/iStock via Getty ImagesVBL Therapeutics (Vascular Biogenics Ltd. (VBLT)) continues to progress their flagship candidate, VB-111, an innovative gene therapy for solid tumors. Recently, the company announced that their Phase III OVAL pivotal trial in ovarian cancer has been amended to add progression-free survival “PFS” as an additional primary endpoint.... |
Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Vascular Biogenics (VBLT)Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coherus Biosciences (CHRS), Vascular Biogenics The post Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Vascular Biogenics (VBLT) appeared first on Smarter Analyst . |
VBLT Price Returns
| 1-mo | 4.95% |
| 3-mo | 13.11% |
| 6-mo | 20.73% |
| 1-year | 82.03% |
| 3-year | -16.79% |
| 5-year | -43.03% |
| YTD | 23.28% |
| 2020 | 57.50% |
| 2019 | 23.71% |
| 2018 | -86.34% |
| 2017 | 46.39% |
| 2016 | -7.79% |
Continue Researching VBLT
Want to do more research on Vascular Biogenics Ltd's stock and its price? Try the links below:Vascular Biogenics Ltd (VBLT) Stock Price | Nasdaq
Vascular Biogenics Ltd (VBLT) Stock Quote, History and News - Yahoo Finance
Vascular Biogenics Ltd (VBLT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...